Cargando…

Outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator and tirofiban

Stroke patients can recover upon intravenous thrombolysis but remain impaired in lacking recanalization. We sought to investigate the clinical effect of systemic thrombolysis with an intravenous bolus of 20 mg recombinant tissue plasminogen activator (rtPA) and an infusion of body-weight adjusted ti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seitz, Rüdiger J., Sukiennik, Judith, Siebler, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490474/ https://www.ncbi.nlm.nih.gov/pubmed/23139853 http://dx.doi.org/10.4081/ni.2012.e9

Ejemplares similares

Clinical safety and possible efficacy of tirofiban in combination with intravenous thrombolysis by recombinant tissue plasminogen activator for early treatment of capsular warning syndrome (CWS)
por: Liu, Yunzhu, et al.
Publicado: (2022)

Prospective pilot study of tirofiban in progressive stroke after intravenous thrombolysis
por: Zhang, Yan, et al.
Publicado: (2022)

Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis
por: Yang, Hung-Wei, et al.
Publicado: (2012)

Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke
por: Huang, Yuyou, et al.
Publicado: (2023)

Safety and Efficacy of Tirofiban During Mechanical Thrombectomy for Stroke Patients with Preceding Intravenous Thrombolysis
por: Huo, Xiaochuan, et al.
Publicado: (2020)

Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis in a Patient with Acute Ischemic Stroke Secondary to Aortic Dissection
por: Hong, Keun-Sik, et al.
Publicado: (2009)

Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: Feasibility and effectivity from an Indian perspective
por: Sharma, S. R., et al.
Publicado: (2008)

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry
por: Matsuo, Ryu, et al.
Publicado: (2014)

Evaluation of Cerebral Perfusion in Patients Undergoing Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis
por: HIRANO, Teruyuki
Publicado: (2015)

Thrombolysis with Systemic Recombinant Tissue Plasminogen Activator in Children: A Multicenter Retrospective Study
por: Zengin, Emine, et al.
Publicado: (2021)

Left ventricular apical thrombus after systemic thrombolysis with recombinant tissue plasminogen activator in a patient with acute ischemic stroke
por: Doepp, Florian, et al.
Publicado: (2005)

A Retrospective Study of thrombolysis with 0.6 mg/kg Recombinant Tissue Plasminogen Activator (rt-PA) in Mild Stroke
por: Yang, Jie, et al.
Publicado: (2016)

Relationship between homocysteine level and prognosis of elderly patients with acute ischemic stroke treated by thrombolysis with recombinant tissue plasminogen activator
por: Li, Juan, et al.
Publicado: (2019)

Mechanical thrombectomy combined with recombinant tissue plasminogen activator thrombolysis in the venous sinus for the treatment of severe cerebral venous sinus thrombosis
por: ZHEN, YONG, et al.
Publicado: (2015)

Intraarterial Tirofiban Thrombolysis for Thromboembolisms During Coil Embolization for Ruptured Intracranial Aneurysms
por: Jeon, Jin Sue, et al.
Publicado: (2012)

Systemic thrombolysis with recombinant tissue plasminogen activator for acute life-threatening Blalock-Taussig shunt obstruction
por: Diaz, Franco, et al.
Publicado: (2016)

Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report
por: Gawehn, Annemarie, et al.
Publicado: (2016)

Effect of glycated hemoglobin index and mean arterial pressure on acute ischemic stroke prognosis after intravenous thrombolysis with recombinant tissue plasminogen activator
por: Liu, Shi-Ying, et al.
Publicado: (2018)

Guidelines for Intravenous Thrombolysis (Recombinant Tissue-type Plasminogen Activator), the Third Edition, March 2019: A Guideline from the Japan Stroke Society
por: TOYODA, Kazunori, et al.
Publicado: (2019)

Angioedema after thrombolysis with tissue plasminogen activator: an airway emergency
por: Rathbun, Kimberly M
Publicado: (2019)

Negative Fluid-Attenuated Inversion Recovery-Based Intravenous Thrombolysis Using Recombinant Tissue Plasminogen Activator in Acute Stroke Patients with Unknown Onset Time
por: Aoki, Junya, et al.
Publicado: (2013)

Effect of glycated hemoglobin index and mean arterial pressure on acute ischemic stroke prognosis after intravenous thrombolysis with recombinant tissue plasminogen activator: Erratum
Publicado: (2019)

Safety and Efficacy of Tirofiban During Intravenous Thrombolysis Bridging to Mechanical Thrombectomy for Acute Ischemic Stroke Patients: A Meta-Analysis
por: Li, Wei, et al.
Publicado: (2022)

Acceleration of Tissue Plasminogen Activator-Mediated Thrombolysis by Magnetically Powered Nanomotors
por: Cheng, Rui, et al.
Publicado: (2014)

Severe thrombocytopenia following tirofiban infusion
por: Panduranga, Prashanth, et al.
Publicado: (2011)

Safety and Efficacy of Tirofiban in Severe Ischemic Stroke Patients Undergoing Mechanical Thrombectomy
por: Cai, Lingxin, et al.
Publicado: (2022)

Impact of SMTP Targeting Plasminogen and Soluble Epoxide Hydrolase on Thrombolysis, Inflammation, and Ischemic Stroke
por: Hasumi, Keiji, et al.
Publicado: (2021)

Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator
por: Ong, Cheung-Ter, et al.
Publicado: (2017)

Local Cerebral Recombinant Tissue Plasminogen Activator Concentrations During Acute Stroke
por: Essig, Fabian, et al.
Publicado: (2021)

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
Publicado: (2012)

Microcatheter-Directed Thrombolysis Using Recombinant Tissue Plasminogen Activator for the Treatment of Acute Superior Mesenteric Artery Embolism: A Case Report
por: Kim, Yang-Won, et al.
Publicado: (2023)

Dramatic thrombolysis after rapid injection of tissue plasminogen activator: A case report
por: Park, Jin-Sung, et al.
Publicado: (2019)

Efficacy and Safety of Tirofiban in Clinical Patients With Acute Ischemic Stroke
por: Han, Bin, et al.
Publicado: (2022)

Tirofiban-induced thrombocytopenia
por: Wang, Jun, et al.
Publicado: (2023)

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
por: Wardlaw, Joanna M, et al.
Publicado: (2012)

Racial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist at Primary Stroke Centers
por: Aparicio, Hugo J., et al.
Publicado: (2015)

Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2016)

Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology
por: Gainey, Jordan, et al.
Publicado: (2018)

Predictors of Intracerebral Hemorrhage in Acute Stroke Patients Receiving Intravenous Recombinant Tissue Plasminogen Activator
por: Chenna, Vijay, et al.
Publicado: (2018)

Quantitatively monitoring acute ischemic stroke patients post recombinant tissue plasminogen activator treatment
por: Liu, Yonge, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jvrstjovq9rno01qfdammgc84h